Key points
Vutrisiran (Amvuttra) is an injection every three months for adults with transthyretin amyloidosis: it switches off production of transthyretin in the liver, lowering its level by roughly 80%.
| Situation | How it helps | What human studies showed |
|---|---|---|
| Amyloid cardiomyopathy | lowers the risk of death from any cause together with recurrent cardiovascular events | HELIOS-B (NEJM, 2025), 655 patients: hazard ratio 0.72 (95% CI 0.56–0.93; p=0.01) [1] |
| Survival in cardiomyopathy | death from any cause 35% lower | through 42 months hazard ratio 0.65 (95% CI 0.46–0.90; p=0.01) [1] |
| Walking and quality of life in cardiomyopathy | function is better preserved | six-minute walk test — 26.5 m difference favouring the drug; KCCQ questionnaire — 5.8 points (both p<0.001) [1] |
| Alongside a stabiliser | the benefit holds in patients taking tafamidis | about 40% of participants were already taking tafamidis, and adding vutrisiran benefited them too [1] |
| Polyneuropathy in the hereditary form | the first indication, since 2022 | — |
How it helps
Two ways to solve one problem
In transthyretin amyloidosis the transport protein transthyretin loses stability, falls apart, and the loose parts clump into amyloid fibrils that deposit in the heart and nerves.
The first is to hold the protein together. That is what stabilisers do: tafamidis and acoramidis bind the four parts of the molecule and stop it coming apart. That approach is covered in the guide on acoramidis.
The second is not to produce the protein at all. No protein, nothing to fall apart. That is vutrisiran's route.
| Stabilisers (tafamidis, acoramidis) | Vutrisiran | |
|---|---|---|
| What they do | Hold existing protein together | Prevent it being made |
| Where they act | In the blood | In liver cells |
| Form | Daily tablets | Injection every 3 months |
| Reduction in transthyretin level | Minimal | About 80% |
How a gene is silenced
A gene is a blueprint. To build a protein from it, the cell first makes a working copy — messenger RNA — and assembly runs off that copy.
A small interfering RNA is a short fragment that recognises a specific copy and marks it for destruction. The blueprint stays untouched, but the working copies never reach the assembly floor, and the protein is not made.
The mechanism was not invented: cells use RNA interference to defend against viruses. Medicine merely learned to aim it at a chosen gene.
Delivery was a separate engineering problem. A carbohydrate address, GalNAc, is attached to the molecule, and liver cells actively take up anything carrying it. Transthyretin is produced chiefly by the liver, so the targeting lands precisely on target — and makes one injection every three months enough.
What the trial showed
▸ HELIOS-B (NEJM, 2025) — 655 patients with transthyretin amyloid cardiomyopathy [1]. The key figure is death from any cause: a 35% reduction means the drug affects not only measurements and wellbeing but how long a person lives. In chronic-disease trials that difference is far from routinely achieved.
▸ HELIOS-A (Amyloid, 2023) — the trial in the hereditary form with polyneuropathy, on which the drug's first indication rests [2].
How it is given
A subcutaneous injection every three months — four injections a year, with no infusions and no hospital visit.
Who should see a doctor first
Tolerability. Adverse events in HELIOS-B: 99% versus 98% on placebo, serious ones 62% versus 67% [1].
Vitamin A
Transthyretin carries thyroid hormone and vitamin A. When its level falls by 80%, vitamin A transport suffers.
Thyroid hormones are not noticeably affected: thyroxine has other carriers. But vitamin A levels genuinely drop, so patients on drugs of this class are prescribed vitamin A at a dose their doctor specifies, and complaints related to night vision are given particular attention.
Who it is not for
▸ Patients with light-chain amyloidosis: a different disease with different treatment.
▸ Anyone without a confirmed diagnosis — treatment begins after scintigraphy or genetic confirmation, not on suspicion.
▸ As a replacement for baseline heart failure therapy.
▸ Anyone unwilling to attend regular follow-up: monitoring vitamin A and cardiac status is part of the treatment.
Bottom line
▸ A different level of intervention: not holding the protein together but preventing its production — about an 80% reduction in transthyretin.
▸ An effect on survival is demonstrated: 35% lower death from any cause through 42 months.
▸ Early diagnosis decides: the earlier the diagnosis, the more intact tissue can be protected.
Treatment can be discussed at a consultation; the drug can be ordered here.
References
1. Fontana M, et al. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025;392(1):33–44. PMID 39213194
2. Adams D, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1–9. PMID 35875890
3. Gillmore JD, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2024;390(2):132–142. PMID 38197816
4. AMVUTTRA (vutrisiran) — US Prescribing Information, Alnylam Pharmaceuticals.
Source: Vutrisiran (Amvuttra): An Injection Every Three Months That Switches Off Production of the Harmful Protein — universum.earth. Dr. Pereligyn.
